REVOLUTION Medicines Inc
Closed
SectorHealthcare
203.64 0.21
Overview
Share price change
24h
Min
203.1
Max
204.78
Income | -644M -1.1B |
|---|---|
EPS | -2.34 |
Employees | 883 |
EBITDA | -184M -621M |
Next Earnings | 4 Nov 2026 |
|---|
Market Cap | 6.2B 45B |
|---|---|
Previous open | 203.43 |
Previous close | 203.64 |
News Sentiment
By Acuity
9%
91%
6 / 339 Healthcare
REVOLUTION Medicines Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
REVOLUTION Medicines Inc Forecast
Sentiment
By Acuity
6 / 339 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About REVOLUTION Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.